# moderate to severe GAD FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/moderate-to-severe-gad

> No upcoming FDA catalysts in moderate to severe GAD; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for moderate to severe GAD?

No upcoming FDA catalysts in moderate to severe GAD; 2 past events are recorded. Press release filed with the SEC (EX-99): "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD." [Calendar and source filings](https://sec-api.dev/indications/moderate-to-severe-gad)

Source: Press release filed with the SEC (EX-99), accession 0001833141-25-000043, https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm (retrieved 2026-11-12). Last confirmed 2025-11-13. Cite: https://sec-api.dev/indications/moderate-to-severe-gad#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 15, 2024 | [HLP004 trial start](https://sec-api.dev/pdufa/hlp004) | HELP | moderate to severe GAD | completed | "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM HLP004 in participants with moderate to severe GAD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm)) |
| March 15, 2024 | [CYB004 trial start](https://sec-api.dev/pdufa/cyb004) | HELP | moderate to severe GAD | completed | "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm)) |

## Drugs

- [HLP004](https://sec-api.dev/pdufa/hlp004) (HELP)
- [CYB004](https://sec-api.dev/pdufa/cyb004) (HELP)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/moderate-to-severe-gad.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "moderate to severe GAD FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/moderate-to-severe-gad

```bibtex
@misc{secapidev_indications_moderate_to_severe_gad_20261116,
  title        = {moderate to severe GAD FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/moderate-to-severe-gad}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_moderate_to_severe_gad_20261116","title":"moderate to severe GAD FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/moderate-to-severe-gad","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
